NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

  • Interventional
  • Not Recruiting
  • NCT03146663
Eligibility Details Visit Clinicaltrials.gov

A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

This study will evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective is to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).

Up to 20 patients will be treated at each dose in Part I of the study. In Part II of the study, one of the treatment dose levels will be selected for further evaluation. The dose selection will be based on clinical and laboratory assessments of patients recruited in Part I. Patients will only participate in either Part I or II. A total of 64 patients will be treated in Part I and Part II combined.

     Eligible consenting patients will receive NUC-1031 by IV infusion on days 1, 8 and 15 of each 28-day cycle. Patients will continue to receive NUC-1031 until the occurrence of disease progression. Patients will undergo imaging every 8 weeks. After disease progression, patients will be followed for overall survival.

Gender
Female

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         1. Provision of signed written informed consent.

         2. Original diagnosis and/or histological confirmation of high-grade serous, high-grade endometrioid, undifferentiated/unclassifiable epithelial ovarian, fallopian tube or primary peritoneal cancer.

         3. Time from the last line of platinum-based chemotherapy of less than 6 months.

         4. Received at least 3 prior chemotherapy-containing regimens.

         5. Age ≥18 years.

         6. Ability to comply with protocol requirements.

         7. Patients are not of childbearing potential or they must agree to use a physical method of contraception.

        Exclusion Criteria:

         1. Disease that progressed while receiving initial line of platinum-based chemotherapy.

         2. Received fewer than 3 prior chemotherapy-containing regimens.

         3. Prior therapy with single-agent gemcitabine.

         4. Prior history of hypersensitivity to gemcitabine.

         5. Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within 21 days of first receipt of study drug. Hormone therapy within 14 days of first receipt of study drug.

         6. Residual side effects from chemotherapy or radiation, which have not gotten better except for nerve pain or tingling or hair loss.

         7. Patients who have a history of another type of cancer diagnosed within the past 5 years, with the exception of adequately treated non-melanoma skin cancer curatively treated cervical cancer or ductal carcinoma in situ (DCIS) of the breast.

         8. Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics.

         9. Presence of any serious illnesses, serious medical conditions, serious medical history, active bacterial or viral infections including hepatitis B or C, or known to be HIV positive.

         10. Currently pregnant, lactating or breastfeeding.

         11. History of blocked intestines because of ovarian cancer, unless fully resolved.

At a Glance

National Government IDNCT03146663

IRB#IRB17-0627

Lead SponsorNuCana plc

Lead PhysicianJohn Moroney

Collaborator(s)N/A

EligibilityFemale
18 Years and up
Not Recruiting